Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:58 PM
Ignite Modification Date: 2025-12-24 @ 11:58 PM
NCT ID: NCT00175058
Eligibility Criteria: INCLUSION CRITERIA Candidates for this study must meet ALL of the following criteria: Pre-PCI: 1. Patient must be \>= 18 years of age 2. AMI must be anterior 3. Patient is experiencing clinical symptoms consistent with anterior AMI of \< 6 hour duration from time of symptom onset until admission to the emergency room 4. Complete medical history, history of AMI, previous coronary interventions, list of medications given within last 24 hours 5. 12-lead qualifying ECG criteria: Anterior infarction (ST-segment elevation \> 1 mm in two or more contiguous leads between V1 and V4 or new left bundle branch block (LBBB) with documentation of LAD system culprit lesion) 6. Patient provides written, Informed Consent 7. Patient and his/her physician agree to all required follow-up procedures and visits 8. Women of childbearing potential who have a negative pregnancy test (applies to female patients only) ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to randomization: 9. Based on coronary anatomy, PCI is indicated for culprit lesion with anticipated use of an Intra-Coronary Stent 10. TIMI 0, I, or II flow is present on the initial angiographic injection of the infarct-related artery 11. Successful angioplasty as documented by \< 50% diameter residual angiographic stenosis within and associated with the culprit lesion and ³ TIMI II flow and no major complications such as perforation or shock 12. Documented time of reperfusion is \< 6 hours from the documented time of symptom onset EXCLUSION CRITERIA Candidates will be excluded from this study if ANY of the following conditions apply: Pre-PCI: 13. Patients with ventricular pseudoaneurysm, VSD, or papillary muscle rupture. 14. Absolute contraindications to anticoagulant therapy, including hemorrhagic diathesis or thrombocytopenia 15. Systemic Arterial pO2 is \< 80 mmHg with supplemental oxygen 16. Placement of an intra-aortic balloon pump (IABP) 17. Patient has had coronary bypass surgery during the 30 day period preceding PCI 18. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or non-ischemic cardiomyopathy 19. Patients requiring cardiopulmonary resuscitation for \> 10 minutes 20. Cardiogenic shock (SBP \< 80 mm Hg for more than 30 minutes unresponsive to fluids or requiring intravenous pressors or placement of an IABP) 21. Expected survival of less than 6 months due to non-cardiac condition 22. Current participation in other investigational device or drug trials that have not finished the primary efficacy endpoint follow-up parameters 23. Patient has had a hemorrhagic stroke during the 6 month period preceding PCI 24. Physician discretion regarding unacceptability for enrollment ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to randomization: 25. Any proximal coronary diameter stenosis \> 40 % that would restrict native flow with the Tracker-38 infusion catheter in place 26. Infarct-related vessels that are either saphenous vein grafts and/or small second order coronary vessels that do not supply significant areas of myocardium 27. Presence of a non-stented coronary dissection upon completion of the PCI procedure 28. Unprotected left main diameter stenosis \> 60% 29. Severe target vessel calcification or tortuosity 30. Multi - vessel disease that in the judgment of the investigator is best treated with emergent or urgent CABG or additional PCI within 30 days 31. In the investigator's opinion, the target vessel is unsuitable for either placing the infusion catheter or treatment with PCI
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00175058
Study Brief:
Protocol Section: NCT00175058